Evidence map›Paper›PMID 36068222›Full record

ArticleNature communications2022

PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest.

Yangyang Yuan, Chenwei Wang, Xuran Zhuang, Shaofeng Lin, Miaomiao Luo, Wankun Deng, Jiaqi Zhou, Lihui Liu, Lina Mao, Wenbo Peng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yangyang Yuan *Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.
Chenwei Wang *MOE Key Laboratory of Molecular Biophysics, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, Institute of Artificial Intelligence, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China.ORCID 0000-0002-0920-8639
Xuran Zhuang *School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Shaofeng Lin *MOE Key Laboratory of Molecular Biophysics, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, Institute of Artificial Intelligence, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China.ORCID 0000-0002-1177-5480
Miaomiao Luo *Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.
Wankun DengMOE Key Laboratory of Molecular Biophysics, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, Institute of Artificial Intelligence, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China.ORCID 0000-0002-5052-9151
Jiaqi ZhouMOE Key Laboratory of Molecular Biophysics, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, Institute of Artificial Intelligence, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China.ORCID 0000-0002-9285-8914
Lihui LiuInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.
Lina MaoInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.
Wenbo PengSchool of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Jian ChenENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200031, China.ORCID 0000-0002-0578-9675
Qiangsong WangInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.
Yilai ShuENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200031, China. yilai_shu@fudan.edu.cn.ORCID 0000-0001-8893-434X
Yu XueMOE Key Laboratory of Molecular Biophysics, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, Institute of Artificial Intelligence, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, China. xueyu@hust.edu.cn.ORCID 0000-0002-9403-6869
Pengyu HuangInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China. huangpengyu@yeah.net.ORCID 0000-0001-8394-7280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein kinase-mediated phosphorylation plays a critical role in many biological processes. However, the identification of key regulatory kinases is still a great challenge. Here, we develop a trans-omics-based method, central kinase inference, to predict potentially key kinases by integrating quantitative transcriptomic and phosphoproteomic data. Using known kinases associated with anti-cancer drug resistance, the accuracy of our method denoted by the area under the curve is 5.2% to 29.5% higher than Kinase-Substrate Enrichment Analysis. We further use this method to analyze trans-omic data in hepatocyte maturation and hepatic reprogramming of human dermal fibroblasts, uncovering 5 kinases as regulators in the two processes. Further experiments reveal that a serine/threonine kinase, PIM1, promotes hepatic conversion and protects human dermal fibroblasts from reprogramming-induced ferroptosis and cell cycle arrest. This study not only reveals new regulatory kinases, but also provides a helpful method that might be extended to predict central kinases involved in other biological processes.

Indexed as

FerroptosisCell CycleCell Cycle CheckpointsDrug Resistance, NeoplasmHumansPhosphorylationProtein Serine-Threonine KinasesProto-Oncogene Proteins c-pim-1PIM1 protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins c-pim-1

Identifiers

PMID36068222
PMCPMC9448736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.